Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class

Mar 22 2023

• By Joseph Haas

Two racers — Competition between 89bio and Akero in NASH is tightening • Source: Shutterstock

Related Content

Intercept, Madrigal Get Ready For NASH Commercialization

Mar 02 2023

Akero Sees Across-The-Board NASH Benefit With Efruxifermin, But Faces Competition

Jun 30 2021

NASH Updates: Intercept Moves Toward Re-Filing, Madrigal De-Risks Phase III

Nov 16 2021

89bio Hopes Akero’s Success In Cirrhotic NASH Is Positive For FGF21 Class

Mar 24 2021

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

Feb 11 2020

Related Companies

89bio, Inc.

Akero Therapeutics, Inc.

Bristol Myers Squibb Company

Intercept Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.